● Recruiting

A Trial of HRS-6209 in Combination With Fulvestrant, Letrozole, HRS-8080, or HRS-1358 in Breast Cancer Patients

Condition: Advanced Unresectable or Metastatic Breast Cancer · Sponsor: Jiangsu HengRui Medicine Co., Ltd.

PhasePhase 1/Phase 2

Planned participants528

Who can joinFemale, 18 Years to 75 Years

Healthy volunteersNo

About this study

The study is being conducted to evaluate the safety, PK and efficacy of HRS-6209 in Combination with Fulvestrant, Letrozole, HRS-8080, or HRS-1358 for advanced unresectable or metastatic breast cancer

This description comes directly from the study's public registry record.

Talk to the study team

Xiaonan Sheng · +86 13524857678 · xiaonan.sheng.xs6@hengrui.com

Always discuss trial participation with your own doctor first.

Locations (1)

Fudan University Shanghai Cancer Center

Shanghai, Shanghai Municipality, China

Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06555068